Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.78
+2.3%
$1.62
$1.03
$2.41
$55.53M-0.53405,691 shs144,405 shs
RZLTD
Rezolute
$7.12
-1.4%
$5.60
$16.00
$24.05
$59.94M4.634,788 shs1.26 million shs
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
$0.00
$0.97
$4.56
$16.16M1.38197,338 shs57,700 shs
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
$0.22
$0.22
$0.08
$0.34
$56.90M2.65,474 shsN/A
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
0.00%+2.30%+9.20%+15.58%-6.32%
RZLTD
Rezolute
-1.11%+1.71%+13.02%+72.82%+48.64%
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
0.00%0.00%0.00%0.00%0.00%
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
2.3779 of 5 stars
3.55.00.00.01.10.00.6
RZLTD
Rezolute
N/AN/AN/AN/AN/AN/AN/AN/A
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
N/AN/AN/AN/AN/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3.00
Buy$4.50152.81% Upside
RZLTD
Rezolute
0.00
N/AN/AN/A
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
0.00
N/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SYN, RZLTD, TRLPF, and ATNM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/A$1.31 per shareN/A
RZLTD
Rezolute
N/AN/AN/AN/A$1.24 per shareN/A
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
N/AN/AN/AN/A$4.95 per shareN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
$7.38M7.71N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-$48.82M-$1.31N/AN/AN/AN/A-100.85%-47.89%N/A
RZLTD
Rezolute
-$20.33MN/A0.00N/AN/A-153.46%-111.71%N/A
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
-$14.27M-$1.21N/AN/AN/AN/A-26.14%-22.74%N/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
-$18.79M-$0.08N/AN/A-254.66%-346.72%-94.54%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/AN/A
RZLTD
Rezolute
N/AN/AN/AN/AN/A
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
N/AN/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/A
10.25
10.25
RZLTD
Rezolute
N/A
3.26
3.26
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
N/A
4.14
4.14
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.64
1.35
0.90

Institutional Ownership

CompanyInstitutional Ownership
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
27.50%
RZLTD
Rezolute
N/A
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
74.38%
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.02%
CompanyEmployeesShares OutstandingFree FloatOptionable
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3031.20 million29.32 millionOptionable
RZLTD
Rezolute
238.42 millionN/ANot Optionable
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
1615.84 million15.50 millionNot Optionable
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
29258.62 millionN/ANot Optionable

Recent News About These Companies

Takeda Pharmaceutical Co. Ltd. ADR
Other OTC Pharmaceuticals - Lithuania
Acerus Reports Second Quarter 2022 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Actinium Pharmaceuticals stock logo

Actinium Pharmaceuticals NYSE:ATNM

$1.78 +0.04 (+2.30%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$1.78 -0.01 (-0.28%)
As of 08/29/2025 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Rezolute OTCMKTS:RZLTD

$7.12 -0.10 (-1.39%)
As of 08/29/2025

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Synthetic Biologics stock logo

Synthetic Biologics NYSEAMERICAN:SYN

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.

Acerus Pharmaceuticals stock logo

Acerus Pharmaceuticals OTCMKTS:TRLPF

$0.22 0.00 (0.00%)
As of 07/21/2023

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.